Member Info for Sheephatch

Best RNS we could have received at this stage. Very very exciting from here.

23% up

A new day and the company now can progress. Bright future. Good luck.

I consider holding onto the rise from yesterday and even finishing in the blue a strong day. You can’t expect explosives everyday. Lots of other Covid shares didn’t perform very well today. The worlds economy collapsing around us and we still finished up. Not bad in my books but everyone to their own. Keep the faith and stay safe.

Very strong day. Time to hold and wait for the news.

16% up

No afraid not.
120 being paid.
Exciting times.

Sell now and possibly regret it,

Over 30% up and still climbing. I thought a pound today but that’s well behind us. Good luck all.

Creeping towards a pound. Could be today.

Good rise on no news and realistically we could still be a few away from the news we want. Let’s hope they can pull the rabbit out the bag and get things expedited and get it done nice and early. I’d imagine they are putting in the hours.

People filling their boots with a 50% discount of where this should be.

Brilliant start to the week.

Getting into Walmart is terrific news. How many products will be the million dollar question ?

14% up at the mo

I think she put something in your tea ! We are off.

With market conditions this looks like another good day for SBTX. Perhaps people coming over from risky pump and dumps. Hope everyone is is keeping well.

Brilliant achievement by the team at GDR. What a brilliant test and hopefully it will prevent much suffering to children around the world.

70p a realistic price tomorrow is the current strong buying continues. Better coverage now bringing in new investors and people understanding the massive upside and potent here.

Professor Tom Wilkinson was appointed as Consultant and Senior Lecturer to a joint post held between the Respiratory and Nutrition BRUs and allied to the faculty of medicine in July 2010. He was subsequently awarded a HEFCE New Blood Senior Lectureship on the basis of his track record of clinically focused research in COPD and respiratory infection having been recognised as European COPD researcher of the year prior to his move from UCL. Since his appointment in Southampton Dr Wilkinson has raised over £7m for COPD and infection research.
Professor Wilkinson’s work focuses on understanding the mechanisms which contribute to the vulnerability to and impact of respiratory infections in patients with chronic lung disease. He is co-lead of the Southampton COPD group and is establishing a cohort of deeply phenotyped patients with COPD to determine the mechanisms driving exacerbations of this disease. Close collaborations in Southampton, London and Oxford have been established to uncover the interaction between nutritional status, immune responses and infection. He has contributed to the establishment of unique ex-vivo and in vivo infection challenge models and is clinical lead on the EVITA programme (ex-vivo models of infection and therapeutics in airways disease) which has established a translational pathway for novel therapies from simple cell systems to complex human viral challenge models.
Tom was appointed to the role of Associate Director of Innovation and Enterprise for the faculty of Medicine and has a lead role in fostering major collaborations between industrial partners and the faculty.